

CIRM Funded Clinical Trials

**AB-205-001 Phase 1b Trial and Related Activities to Support Clinical Development of AB-205**

<b>Disease Area:</b>	Blood Cancer
<b>Investigator:</b>	Edward Kavalerchik
<b>Institution:</b>	Angiocrine Bioscience, Inc.
<b>CIRM Grant:</b>	CLIN2-11371
<b>Award Value:</b>	\$6,192,579
<b>Trial Sponsor:</b>	Angiocrine Bioscience, Inc.
<b>Trial Stage:</b>	Phase 1
<b>Trial Status:</b>	Launching
<b>Targeted Enrollment:</b>	N/A

**Details:**

Angiocrine Bioscience Inc. will use genetically engineered cells, derived from cord blood, to see if they can help alleviate or accelerate recovery from the toxic side effects of chemotherapy for people undergoing treatment for lymphoma and other aggressive cancers of the blood or lymph system.

**Design:**

First in human, Phase 1, multi-center trial

**Goal:**

Safety

**News about this clinical trial:**

Stem Cell Agency Board approves 50th clinical trial

**Source URL:** <https://www.cirm.ca.gov/clinical-trial/ab-205-001-phase-1b-trial-and-related-activities-support-clinical-development-ab-205>